FDA granted accelerated approval of EGFR and MET bispecific antibody amivantamab and TKI mobocertinib as targeted drugs for EGFR exon 20 insertion in advanced non-small cell lung cancer after chemotherapy (10). Here, EGFR is linked to non-small cell lung carcinoma.